A dual-mechanism fat loss stack combining semaglutide's appetite suppression and GLP-1-mediated metabolic benefits with tesamorelin's targeted visceral fat reduction through GHRH agonism. Semaglutide promotes a sustained caloric deficit and improves insulin sensitivity, while tesamorelin specifically mobilises deep abdominal visceral adipose tissue by stimulating pulsatile GH release. The two agents operate through entirely non-overlapping pathways and address different fat compartments.
Mechanism
Reduces appetite and caloric intake via GLP-1 receptor agonism, improves insulin sensitivity, and drives broad body composition improvements — serving as the primary overall fat loss driver of the stack.
Specifically targets visceral adipose tissue via GHRH-stimulated GH pulses that preferentially mobilise deep abdominal fat, addressing a metabolically harmful fat depot that GLP-1 agonism alone may not fully resolve.
Dual-pathway activation
Semaglutide × Tesamorelin
Semaglutide is an FDA-approved prescription GLP-1 agonist carrying a boxed warning for thyroid C-cell tumour risk (observed in rodents; human risk not established). It requires a licensed prescriber and is contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. Tesamorelin (Egrifta) is FDA-approved only for HIV-associated lipodystrophy; its use for general fat loss is off-label and outside its approved indication. This is a prescription-only combination not appropriate for unsupervised use.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial)
Effects of tesamorelin (TH9507) in HIV-infected patients with abdominal fat accumulation
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV-infected patients
A mitochondrial-targeted combination pairing two peptides with distinct but complementary mechanisms. MOTS-c enhances glucose metabolism and AMPK signaling while SS-31 (Elamipretide) stabilizes cardiolipin in the inner mitochondrial membrane, protecting against oxidative damage. Researched in contexts of aging, metabolic dysfunction, and exercise performance.
AOD-9604, a C-terminal fragment of human growth hormone associated with selective lipolytic activity, is paired with Tirzepatide's dual GIP and GLP-1 receptor agonism for appetite regulation and energy balance. The combination is explored for addressing fat reduction through complementary peripheral and central mechanisms.
Hexarelin is one of the most potent synthetic GHRP compounds, associated with robust GH release and additional cardioprotective receptor activity. Mod GRF 1-29 (CJC-1295 without DAC) is a truncated GHRH analog that provides pulsatile GH stimulation without pituitary desensitization. This pairing is commonly researched for maximizing GH secretion through complementary GHRH and GHRP receptor activation.
⚠ Educational Use OnlyPeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Free newsletter
The Peptide Research Digest
Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.
Prices, providers, and published evidence — tracked independently, never an affiliate code. Get research updates as the data grows.
Free · occasional research updates only · unsubscribe in one click
Already a member? Sign in